baltimore,MicroCap Company Spotlight

[Rickey Ware]

Wilton Key,

Genex Pharmaceutical, Inc.(OTCBB: GENX)

Biotech Sizzle with Sales and Earnings!

Treating Bone Related Injuries in China

Revenues three months ended June 30, 2004: $525,750 vs. $98,763 year ago period

Net INC0ME three months ended June 30, 2004: $151,904 vs. ($23,929)year ago period (Source: 10Q 8/16/04)

Look how these Chinese Companies trading in the USA did and what they would've made your portfolio look like if you had the scoop on them: (Big M0NEY Was Made in These Stocks by Savvy Investors Who Timed Them Right)

(OTCBB:CAAS):Closed September 2, 2003 at $4.00. Closed December 31, 2003: $16.65, Up 316%

OTCBB:CWTD):Closed January 30, 2004 at $1.50. Closed February 17th at $7.90, Up 426%

Ordinary Investors Like You are Getting Filthy, Stinking Ri'ch in Tiny Stocks No One has Ever Heard of Until Now.

This Biotech Bad Boy (GENX) is already out of Stealth Mode and is top line revenue producing! Do you see where we're going with this? Biotech Sizzle with Sales and Earnings!

About Genex Pharmaceutical, Inc. (Product Distribtued to 400 Hospitals in 22 Provinces)

Genex Pharmaceutical, Inc. is a biomedical technology company with distinctive proprietary technology for an orthopedic device that treats bone-related injuries. Headquartered in Tianjin, China, the Company manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400 hospitals in 22 provinces throughout mainland China. RBX is approved by the State Food and Drug Administration (SFDA) in China (the Chinese government agency that regulates drugs and medical devices). RBX offers a modern alternative to traditional methods of treating orthopedic injuries. (Source: News Release 7/27/04)

Recent Press Release Headlines: (New Product Tested and Large Acquisition in the Works!)

*Genex Pharmaceutical Adopts New Proprietary Technology, Substantially Reduces Manufacturing Costs, Sees Positive Impact to Earnings

*Genex Pharmaceutical Signs Letter of Intent to Acquire One of the World's Largest Producers of Vitamin B1

*Genex Pharmaceutical Sees Strong Earnings Growth for 2004 and 2005

*Genex Pharmaceutical 2nd Quarter Revenue Up 432%, Gross PR0FIT Up 380%, Net INC0ME Soars, Sees Continued Earnings Momentum for Remainder of 2004

*Genex Pharmaceutical's Micro-Particle RBX Medical Product Expands to the Dental Markets

*Could this be a "Rising Star Stock" for your portfolio? You may easily agree that the company is doing some dynamic things. Some of these small stocks have absolutely EXPLODED in price recently.

*You may want to consider the "Chinese Fortune Cookie" Strategy: Rising Star Chinese Companies trading in the US.. Consider adding GENX to your portfolio today!

DIS-CLAIMER: Information within this ema-il contains "F0RWARD looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "F0RWARD looking statements."F0RWARD looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. F0RWARD looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur. As with many micro-cap stocks, today's company has additional risk factors worth noting. Those factors include: a limited operating history: the company advancing cash to related parties and a shareholder on an unsecured basis: one vendor, a related party through a majority stockholder, supplies ninety-seven percent of the company's raw materials: reliance on two customers for over fifty percent of their business and numerous related party transactions and the need to raise capital.These risk factors and others are fully detailed in the company's SEC filings. We urge you to read them before you invest. The Publisher of this letter does not represent that the information contained in this message states all material facts or does not omit a material fact necessary to make the statements therein not misleading.All information provided within this ema-il pertaining to investing, ST0CKS or securities must be understood as information provided and not investment advice. The Publisher of this letter advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this ema-il. None of the material within this report shall be construed as any kind of investment advice or solicitation. Many of these companies are on the verge of bankruptcy. You can lose all your money by investing in this stock. The Publisher of this letter is not a registered investment ADVIS0R. Subscribers should not view information herein as legal, tax, accounting or investment advice. Any reference to past performance(s) of companies are specially selected to be referenced based on the favorable performance of these companies. You would need perfect timing to acheive the results in the examples given. There can be no assurance of that happening. Remember, as always, past performance is never indicative of future results and a thorough due diligence effort, including a review of a company's filings, should be completed prior to investing.The Publisher of this letter has no relationship with CAAS and CWTD. (Source for Price Information:Yahoo Finance Historical). In compliance with the Securities Act of 1933, Section17(b),The Publisher of this letter discloses the receipt of twenty four thousand dollars from a third party,(DMI, Inc) not an officer, director or affiliate shareholder for the circulation of this report. Be aware of an inherent conflict of interest resulting from such compensation due to the fact that this is a paid adver-tisement and is not without bias. All factual information in this report was gathered from public sources, including but not limited to Company Websites, SEC Filings and Company Press Releases. The Publisher of this letter believes this information to be reliable but can make no guar-antee as to its accuracy or completeness. Use of the material within this ema-il constitutes your acceptance of these terms.

choreography prostate brew fragment derelict blight operable caiman revolve lifo zambia hackberry toothpaste usa impassion pow invoice salvador stark puppet bifocal rendition reprise auntie arching tty wick clausen rubble dim alleviate bowdoin bedspread ordinance atlantic cranelike booky countrymen agway allot ,hoyt fiction lance instead compress superfluity swatch boxwood walrus bipartisan spinnaker gunshot allowance kline circumvent axes stamp arsine pedagogue cochlea encryption dominant corporeal nasturtium exert houghton judson japan dirichlet orchid goddess atheism grandchildren antagonistic houdini helvetica .bibliophile miterwort forbidding call timeout guffaw pillar postprocess bentley eluate alumna rabbit johanson crumb cadent casanova ideolect appear spoilage bronchitis born fairchild coquette beetle decrease brainchild appendix postscript knuckle .